Stempeutics Research Private Limited, a active private limited company, was established on 16 January 2006 in Bengaluru, Karnataka, India. Engaging in biotechnology within the professional, scientific and technical sector, it holds CIN: U73100KA2006PTC038256. Registered under ROC Roc Bangalore. it is unlisted. It has an authorized capital of ₹65.00 Cr and a paid-up capital of ₹63.62 Cr.
It upholds a compliant status. Employing 27 professional, Its leadership includes Jaideep Ashok Gogtay (Nominee Director), Hebri Sudarshan Ballal (Director), Umang Vohra (Director). Past directors included Subhaskrishna Hebri Ballal, Jaideep Ashok Gogtay, Chandrasekaran Mahadevan. It holds ₹1.89 Cr open charges and ₹2.84 M settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at 3Rd Floor, #143, 212-215,Epip Industrial Area Hoodi Village,K.R.Puram, Hobli, Bengaluru, Karnataka, 560066.
U73100KA2006PTC038256
038256
16 January 2006
₹65.00 Cr
₹63.62 Cr
Roc Bangalore
Unlisted
Active
Explore comprehensive insights into Stempeutics Research Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Jaideep Ashok Gogtay | Nominee Director | 28 Mar 2019 | Current |
| Hebri Sudarshan Ballal | Director | 19 Jan 2012 | Current |
| Umang Vohra | Director | 24 Feb 2023 | Current |
| Anurag Bagaria | Director | 27 Jun 2019 | Current |
| Manohar Balu Narasimhan | Managing Director | 26 Aug 2009 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 30 Jun 2011 | Past |
| Pramod Abcsdd | Director | 05 Feb 2014 | Past |
| Pramod Abcsdd | Director | 12 Nov 2007 | Past |
| Pramod Abcsdd | Company Secretary | - | Past |
| Pramod Abcsdd | Director | 05 Feb 2014 | Past |
| Pramod Abcsdd | Additional Director | 16 Jul 2023 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Stempeutics Research Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 357.64% increase. The company also saw a substantial improvement in profitability, with a 49.71% increase in profit. The company's net worth Soared by an impressive increase of 52.97%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Stempeutics Research had a promoter holding of 46.49% and a public holding of 53.51%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹18,920,000.00
₹2,844,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Dec 2011 | Biotechnology Industry Research Assistance Council | ₹1.89 Cr | Open |
| 19 Nov 2021 | Hdfc Bank Limited | ₹2.84 M | Satisfied |
Explore comprehensive loan charge details -
Stempeutics Research has a workforce of 27 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Stempeutics Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stempeutics Research's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on A charge registered on 19 Nov 2021 via Charge ID 100506817 with Hdfc Bank Limited was fully satisfied on 17 Oct 2025. was documented.
Progress on Stempeutics Research Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was documented.
The activity Sheetal Somani was appointed as a Company Secretary was appointed as a Company Secretary on 30 Jun 2025 & has been associated with this company since 4 months 30 days . was completed.
The activity Stempeutics Research Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore. was completed.
The activity Umang Vohra was appointed as a Director was appointed as a Director on 24 Feb 2023 & has been associated with this company since 2 years 9 months . was completed.
A charge with Hdfc Bank Limited amounted to Rs. 0.28 Cr with Charge ID 100506817 was registered on 19 Nov 2021. was recorded as a recent event.
When you have a non-healing diabetic foot ulcer, the current treatments may not work and can even lead to amputation. But Stempeucel-DFU, a new drug being tested in a Phase 3 trial, could change that. It's made from stem cells and could help heal the ulcer and reduce its size. If it works, it could make a big difference for patients and improve their quality of life..
Under the agreement, Cipla will get exclusive marketing rights for five years in India for the diabetic foot ulcer (DFU) product. Stempeutics will manufacture and supply the product to Indian company, the company said..
Kemwell will take a minority stake in Stempeutics and invest up to Rs 95 crore based on certain milestones as well as establish a world class cGMP cell therapy manufacturing  facility  at  Kemwell's  facility  in  Bengaluru..
Founded in 2006 by Manipal Education and Medical Group (MEMG), Stempeutics later entered into an alliance with Cipla in 2009. It is an advanced clinical stage biotech firm..
The CIN of Stempeutics Research Private Limited is U73100KA2006PTC038256.
Stempeutics Research Private Limited is headquartered at 3Rd Floor, #143, 212-215,Epip Industrial Area Hoodi Village,K.R.Puram, Hobli, Bengaluru, Karnataka, 560066.
Stempeutics Research Private Limited was incorporated on 16 January 2006.
The current directors of Stempeutics Research Private Limited are
The primary industry of Stempeutics Research Private Limited is Professional, Scientific And Technical.
Stempeutics Research Private Limited is unlisted.
The authorized capital of Stempeutics Research Private Limited is ₹65.00 Cr, and the paid-up capital is ₹63.62 Cr.
The compliance status of Stempeutics Research Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX